Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.64 |
| ▸ | NSD2 | O96028 | 1/20 | 0.62 |
| ▸ | USP2 | O75604 | 1/20 | 0.59 |
| ▸ | APEX1 | P27695 | 1/20 | 0.59 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.59 |
| ▸ | ATM | Q13315 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | BLM | P54132 | 1/20 | 0.57 |
| ▸ | AGER | Q15109 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | ASPH | Q12797 | 1/20 | 0.54 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3715714 | 1.00 | KMT2A (0.64) | KMT2ANSD2USP2APEX1MAPK8 | |
| SCHEMBL1724926 | 0.88 | NSD2 (0.59) | KMT2ANSD2USP2MAPK8ATM | |
| SCHEMBL8154709 | 0.88 | KMT2A (0.80) | KMT2ANSD2USP2APEX1MAPK8 | |
| SCHEMBL28262630 | 0.85 | KMT2A (0.60) | KMT2ANSD2USP2KDM4EALDH1A1 | |
| SCHEMBL31026221 | 0.83 | EGLN2 (0.68) | KMT2ANSD2MAPK8ATMALDH1A1 | |
| SCHEMBL31026200 | 0.83 | HTT (0.56) | KMT2ANSD2MAPK8ATMKDM4E | |
| SCHEMBL3958929 | 0.82 | KMT2A (0.61) | KMT2ANSD2MAPK8ATMKDM4E | |
| SCHEMBL31026208 | 0.82 | KMT2A (0.61) | KMT2ANSD2MAPK8ATMALDH1A1 | |
| SCHEMBL7138975 | 0.82 | KMT2A (0.61) | KMT2ANSD2MAPK8ATMALDH1A1 | |
| SCHEMBL3182140 | 0.80 | NSD2 (0.68) | KMT2ANSD2USP2APEX1MAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7709644-B2 | Process for the enantiomeric enrichment of cis-8-benzyl-7,9-dioxo-2,8-diazabicyclo[4.3.0]nonane | LANXESS DEUTSCHLAND GMBH (DE) | 2010-05-04 | — | — | US | claimed |
| US-20070213536-A1 | Process for the enantiomeric enrichment of cis-8-benzyl-7,9-dioxo-2,8-diazabicyclo[4.3.0]nonane | LANXESS DEUTSCHLAND GMBH (DE) | 2007-09-13 | — | — | US | claimed |
| EP-1375501-B1 | Process for enantiomeric enrichment of cis-8-benzyl-7,9-dioxo-2,8-diazabicyclo(4.3.0)nonane using simulated moving bed chromatography | LANXESS DEUTSCHLAND GMBH (DE) | 2005-11-02 | — | — | EP | claimed |
| US-20040044205-A1 | Process for the enantiomeric enrichment of cis-8-benzyl-7,9-dioxo-2,8-diazabicyclo[4.3.0]nonane | LANXESS DEUTSCHLAND GMBH (DE) | 2004-03-04 | — | — | US | claimed |
| US-7709644-B2 | Process for the enantiomeric enrichment of cis-8-benzyl-7,9-dioxo-2,8-diazabicyclo[4.3.0]nonane | LANXESS DEUTSCHLAND GMBH (DE) | 2010-05-04 | — | — | US | disclosed |
| US-20070213536-A1 | Process for the enantiomeric enrichment of cis-8-benzyl-7,9-dioxo-2,8-diazabicyclo[4.3.0]nonane | LANXESS DEUTSCHLAND GMBH (DE) | 2007-09-13 | — | — | US | disclosed |
| US-20040044205-A1 | Process for the enantiomeric enrichment of cis-8-benzyl-7,9-dioxo-2,8-diazabicyclo[4.3.0]nonane | LANXESS DEUTSCHLAND GMBH (DE) | 2004-03-04 | — | — | US | disclosed |
| US-6566523-B1 | Reacting mixtures of enantiomers with (-)-2,3:4,6-di-O-isopropylidene-2-keto-L-gulonic acid (or its hydrates) to form salts | BAYER AKTIENGESELLSCHAFT (DE) | 2003-05-20 | — | — | US | disclosed |
| US-6458954-B2 | HYDROGENATING A PYRIDINE COMPOUND USING HYDROGENATION CATALYSTS (PALLADIUM ON CARBON) AND AROMATIC HYDROCARBON SOLVENT (BENZENE, XYLENE) | BAYER AKTIENGESELLSCHAFT (DE) | 2002-10-01 | — | — | US | disclosed |
| US-20010056186-A1 | Hydrogenating a pyridine compound using hydrogenation catalysts (palladium on carbon) and aromatic hydrocarbon solvent (benzene, xylene) | LANXESS DEUTSCHLAND GMBH (DE) | 2001-12-27 | — | — | US | disclosed |
| CN-1036005-C | Pharmaceutical composition containing 7-bicyclic substituted-3-quinolone carboxylic acid derivative and process for preparing same | BAYER AG (DE) | 1997-10-01 | — | — | CN | disclosed |
| US-5607942-A | BACTERICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1997-03-04 | — | — | US | disclosed |
| US-5416096-A | 7-(1-pyrrolidinyl)-3-quinolone carboxylic acid derivatives as antibacterial agents and feed additives | BAYER AKTIENGESELLSCHAFT (DE) | 1995-05-16 | — | — | US | disclosed |
| CN-1027165-C | Process for preparing 7-ring substituted-3-quinolone carboxylic acid derivatives | BAYER AG (DE) | 1994-12-28 | — | — | CN | disclosed |
| US-5059597-A | Animal growth regulators; enterobacter | BAYER AKTIENGESELLSCHAFT (DE) | 1991-10-22 | — | — | US | disclosed |
| US-4990517-A | 7-(1-pyrrolidinyl)-3-quinolone- and -naphthyridonecarboxylic acid derivatives as antibacterial agents and feed additives | BAYER AKTIENGESELLSCHAFT (DE) | 1991-02-05 | — | — | US | disclosed |
| CN-1039589-A | 7- (1-pyrrolidinyl) -3-quinolone-and 1, 5-naphthyridonecarboxylic acid derivatives and process for preparing same | BAYER AG (DE) | 1990-02-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010056186-A1 | Hydrogenating a pyridine compound using hydrogenation catalysts (palladium on carbon) and aromatic hydrocarbon solvent (benzene, xylene) | HPD, AHR, HRH3 | KMT2A 361/4885NSD2 220/4885USP2 1232/4885 |
| US-20040044205-A1 | Process for the enantiomeric enrichment of cis-8-benzyl-7,9-dioxo-2,8-diazabicyclo[4.3.0]nonane | CYP1B1, DECR1, SPIN2B | KMT2A 3034/4885NSD2 1825/4885USP2 971/4885 |
| US-20070213536-A1 | Process for the enantiomeric enrichment of cis-8-benzyl-7,9-dioxo-2,8-diazabicyclo[4.3.0]nonane | CYP1B1, CYP8B1, CCR8 | KMT2A 1869/4885NSD2 1337/4885USP2 993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.